Streetbeat News

BEAT

HeartBeam, Inc.

https://www.heartbeam.com

Industry

Medical - Healthcare Information Services

HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.

Open

2.35

Mkt cap

63M

Volume

40K

High

2.52

P/E Ratio

-4.25

52-wk high

3.39

Low

2.35

Div yield

N/A

52-wk low

1.06

Benchmark analyst Bill Sutherland has reiterated a Speculative Buy rating on HeartBeam (NASDAQ:BEAT) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 4:05 pm

FedEx Corporation (NYSE:FDX) shares surged approximately 12% in pre-market trading after reporting Q3 earnings that exceeded expectations and announcing a new $5 billion share repurchase program. Other stocks also showed significant movement in pre-market trading, with notable gainers including Murano Global Investments PLC and Nova LifeStyle, Inc., and losers such as Lululemon Athletica Inc. and NIKE, Inc.

Portfolio Pulse from Avi Kapoor

March 22, 2024 | 12:10 pm

HeartBeam (NASDAQ:BEAT) reported its Q4 earnings with an EPS of $-0.13, matching the estimated earnings. However, revenue did not show growth compared to the same period last year. Following a similar earnings miss last quarter, the share price dropped by 10.0% the next day.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 8:15 pm

HeartBeam (NASDAQ:BEAT) reported its Q4 2023 earnings with a GAAP EPS of $(0.13), which was in line with the analyst consensus estimate. The company's quarterly losses matched expectations.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 8:14 pm

Numerous companies are scheduled to report their quarterly earnings on March 20, 2024, with expectations ranging from significant profits to losses. Notable mentions include BioNTech with projected earnings of $2.64 per share, PDD Holdings expecting $1.60 per share, and Micron Technology anticipated to report a loss of $0.26 per share. The diversity in performance across sectors highlights the varied economic landscape.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 9:32 am

HeartBeam (NASDAQ:BEAT) is scheduled to release its quarterly earnings report on March 20, 2024, with an expected EPS of $-0.13. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historical data shows a correlation between earnings performance and stock price movement, with shares currently trading at $2.32, reflecting a 7.6% decrease over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 3:02 pm

Heartbeam Inc (NASDAQ:BEAT) shares increased by 3.5% to $2.35, after reaching a session high of $2.70, without any company-specific news. The company recently announced securing two new patents for its vectorelectrocardiography (VECG) technology, aimed at transforming cardiac care with portable devices. These patents cover a mobile cardiac monitoring device and a wrist-based ECG system. HeartBeam does not pay dividends but focuses on innovation and technology development to create shareholder value.

Portfolio Pulse from Henry Khederian

March 12, 2024 | 4:07 pm

In Thursday's intraday session, several health care stocks experienced significant movements. Notably, Psyence Biomedical, ZyVersa Therapeutics, Creative Medical Tech, HeartBeam, Ocean Biomedical, and Quantum-Si saw their stock prices increase by over 20%. Conversely, Avid Bioservices, Aptorum Gr, Nexalin Technology, BeyondSpring, PepGen, and Viking Therapeutics faced declines, with some dropping by over 30%. These movements reflect notable volatility within the health care sector.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 5:31 pm

HeartBeam, Inc. has been granted two new US patents for its innovative cardiac monitoring technology. These patents strengthen the company's intellectual property portfolio and underscore its commitment to advancing cardiac care through technology. The patents cover key aspects of HeartBeam's technology, which is designed to improve the detection and monitoring of cardiac events, potentially leading to better patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 1:34 pm

In Wednesday's after-market session, several healthcare stocks showed significant movement. SCWorx (WORX) led the gainers with a 60.8% increase, while Nexalin Technology (NXL) experienced the largest drop among the losers, falling 14.4%. Notable mentions include IO Biotech (IOBT) and Vicarious Surgical (RBOT), which released their Q4 earnings recently, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 9:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.